Alpha Cognition Announces Pricing of Public Offering

VANCOUVER, British Columbia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and including iA Private Wealth Inc. (collectively, the "Agents"), have agreed to sell 8,350,000 units ("Units") of the Company at a price of $1.50 per Unit (the "Issue Price") for aggregate gross proceeds of approximately $12.5 million (the "Offering"). Each Unit will consist of one common share in the capital of Alpha (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.75 for a period of 24 months from the closing date of the Offering.